Forecast

The analysts' average price target is +2,98€ (+1.886,67%). The median is +2,57€ (+1.613,33%).

Buy	10
Hold	5
Sell	2

News Go to news feed

Gossamer Bio secures up to $250 million via private placement

Gossamer Bio has entered into a purchase agreement for up to approximately $250 million in securities. Of that amount, $150 million is committed, including $25 million at the first closing and an additional $125 million contingent on FDA acceptance of the NDA for Seralutinib, which the company plans to submit in September 2026. In addition, exercisable warrants upon approval could raise up to roughly $100 million. Gossamer plans to use the proceeds for the clinical development and potential commercialization of Seralutinib and expects that revenues and existing cash will fund operations through 2028. » More on de.investing.com
Gossamer Bio plans Seralutinib NDA for September 2026 and regains worldwide rights

Gossamer Bio will submit a regulatory filing for Seralutinib in pulmonary arterial hypertension in September 2026 after a productive pre-NDA Type B meeting with the FDA; a potential FDA decision could come in Q3 2027. The company has reacquired global development and commercialization rights for Seralutinib from Chiesi with no upfront payment; Chiesi instead receives a $5 million one-time settlement and retains a capped royalty on future net sales. Shareholders approved the conversion of convertible notes and a reverse stock split, and cash on hand was preliminarily about $57 million. The combination of regulatory progress, full commercial rights and an improved capital structure drove the premarket stock up 37.7%. » More on de.investing.com
Gossamer Bio reaches 90.5% acceptance rate in bond exchange

Gossamer Bio reports that holders of 5.00% convertible senior notes (due 2027) have tendered notes with a principal amount of $181.1 million, representing a 90.5% acceptance rate. The outstanding notes are being exchanged for new, senior secured 7.50% convertible senior notes (due 2030) of up to $65.2 million principal amount, approximately 254.2 million common shares, 33.4 million pre-funded warrants and 135.8 million purchase warrants; settlement is scheduled for Thursday. The transaction lowers the required minimum tender threshold from 98% to 90.5% and effectively removes all covenants and certain events of default; newly issued shares will be subject to a transfer restriction until the annual meeting on June 5, 2026. Gossamer faces significant financial challenges (debt $203 million, market capitalization $47 million) and has been rated "WEAK" by InvestingPro; the exchange offer remains open to remaining noteholders until June 16, 2026. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2023, Gossamer Bio has already paid 0,12€ in dividends. The last payout was in January 2023.

Financials

In the last quarter, Gossamer Bio had revenue of 8.09m€ and net profit of 14.81m€

(EUR)	Jun 2026	YoY
Revenue	+8.09m	16,96%
Gross profit	+8.09m	16,96%
Net profit	+14.81m	145,60%
EBITDA	−62.64m	109,05%

Fundamentals

Metric	Value
Market capitalization	+71.48m€
Number of shares	488.85m
52-week high/low	+3,32€ - +0,0978€
Dividends	No
Beta	2,01
P/E ratio	−0,30
PEG ratio	+0,15
P/B ratio	−0,42
P/S ratio	+1,56

Company profile

Gossamer Bio, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entdeckung, den Erwerb, die Entwicklung und die Vermarktung von Therapeutika in den Krankheitsbereichen Immunologie, Entzündungen und Onkologie in den Vereinigten Staaten konzentriert. Das Unternehmen entwickelt GB002, einen inhalativen, niedermolekularen Thrombozyten-Wachstumsfaktor-Rezeptor (PDGFR), koloniestimulierenden Faktor-1-Rezeptor (CSF1R) und c-KIT-Inhibitor zur Behandlung der pulmonalen arteriellen Hypertonie; GB004, einen oral zu verabreichenden niedermolekularen Wirkstoff zur Behandlung von entzündlichen Darmerkrankungen; GB5121, ein oraler, irreversibler, kovalenter, niedermolekularer Inhibitor der Bruton-Tyrosinkinase zur Behandlung von primären Lymphomen des Zentralnervensystems; und GB7208, ein oraler, niedermolekularer BTK-Inhibitor zur Behandlung von Multipler Sklerose. Das Unternehmen hat Lizenzvereinbarungen mit Pulmokine, Inc. zur Entwicklung und Vermarktung von GB002 und verwandten Backup-Substanzen sowie mit Aerpio Pharmaceuticals, Inc. zur Entwicklung und Vermarktung von GB004 und verwandten Substanzen. Das Unternehmen war früher als FSG, Bio, Inc. bekannt und änderte 2017 seinen Namen in Gossamer Bio, Inc. Gossamer Bio, Inc. wurde im Jahr 2015 gegründet und hat seinen Hauptsitz in San Diego, Kalifornien.